Grumstrup Simonsen Malte, Fenger Carlander Amanda-Louise, Kronberg Jakobsen Kathrine, Grønhøj Christian, Von Buchwald Christian
Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.
Acta Oncol. 2025 Jan 28;64:156-166. doi: 10.2340/1651-226X.2025.41366.
Coronavirus disease 2019 (COVID-19) caused a need for reorganization in the healthcare systems. First, we aimed to determine the impact of the COVID-19 pandemic on time to treatment in head and neck cancer (HNC) patients. Second, we aimed to determine the impact of COVID-19 on tumor stage and changes in treatment regimens used.
A systematic search in PubMed and Embase was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Inclusion criteria were: (1) Studies including patients with head and neck squamous cell carcinomas; (2) Studies containing a comparison of time to treatment; (3) Studies containing a well-defined time interval with restrictions on health care due to COVID-19 and a well-defined time interval without restrictions.
A total of 19 studies were included comprising 24,898 patients treated for HNC cancer. Six studies (10.1% of the patients) reported an increase in waiting time within at least one interval, while seven studies reported a decrease (83.2% of the patients), and six studies found no significant effect. No changes in treatment modalities were observed. Seven of 15 studies (12.7% of the patients) observed an increase in either overall stage, size, or tumor node and metastasis classification during the COVID-19 pandemic. Among these, two studies reported increased waiting times as well.
The impact of the COIVD-19 pandemic on time to treatment was heterogenous and subject to considerable intercountry and interregional variations. A tendency toward a higher T-classification was observed. In conclusion, otorhinolaryngology departments demonstrated resilience, as the pandemic led to only slight alterations in time to treatment.
2019年冠状病毒病(COVID-19)导致医疗系统需要进行重组。首先,我们旨在确定COVID-19大流行对头颈部癌(HNC)患者治疗时间的影响。其次,我们旨在确定COVID-19对肿瘤分期以及所用治疗方案变化的影响。
根据系统评价和Meta分析的首选报告项目指南,在PubMed和Embase中进行了系统检索。纳入标准为:(1)研究包括头颈部鳞状细胞癌患者;(2)研究包含治疗时间的比较;(3)研究包含因COVID-19导致医疗保健受限的明确时间间隔和无限制的明确时间间隔。
共纳入19项研究,包括24,898例接受HNC治疗的患者。六项研究(占患者的10.1%)报告至少在一个时间间隔内等待时间增加,而七项研究报告等待时间减少(占患者的83.2%),六项研究未发现显著影响。未观察到治疗方式的变化。15项研究中的7项(占患者的12.7%)在COVID-19大流行期间观察到总体分期、大小或肿瘤淋巴结转移分类增加。其中,两项研究也报告了等待时间增加。
COVID-19大流行对治疗时间的影响是异质性的,并且存在相当大的国家间和地区间差异。观察到T分类有升高的趋势。总之,耳鼻喉科表现出了韧性,因为大流行仅导致治疗时间有轻微改变。